Uppsala, October 1, 2019. Lobsor Pharmaceuticals AB today announced that Lecigon has been approved, and that the Swedish Medical Products Agency (MPA) has confirmed End of Procedure according to the European Mutual Recognition Procedure (MRP) including Denmark, Finland and Norway.
Ulf Rosén, Co-founder of Lobsor comments: “We are delighted to have now received confirmation of End of Procedure, particularly since it came two months earlier than expected.”
The approval follows the Swedish marketing authorization for Lecigon which was granted in October 2018. Immediately after the MRP